Close Menu

NEW YORK – Bio-Techne said today that the Medicare Administrative Contractor (MAC) National Government Services issued a final Local Coverage Decision (LCD) for its ExoDx Prostate IntelliScore (EPI) test for men who are being considered for an initial prostate biopsy.

The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1, Bio-Techne said. More than 60 million Medicare beneficiaries will be covered for the EPI test by then, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.